FLXN On Track, IMNM Discovers Antibodies To Fight S. African Variant, RIGL In Deal With LLY

(RTTNews) - Today's Daily Dose brings you news about the progress in Flexion Therapeutics' pipeline; Immunome's coronavirus research program; Pfizer/BioNTech testing COVID-19 vaccine in pregnant women; and Rigel's deal with Lilly to develop RIPK1 inhibitors.

Read ona?¦

1. Flexion to Test High Dose of FX201 In Osteoarthritis

Flexion Therapeutics Inc. (FLXN) has decided to advance its gene therapy product candidate FX201 into the high dose cohort of the Phase 1 dose-escalation trial in osteoarthritis, following positive Data Monitoring Committee review of mid dose safety data.

The company has also expanded the trial to include up to 20 additional patients in both the low and mid dose treatment groups.